Identification and enrichment of cell subpopulations
AssigneeStem Centrx, Inc.
InventorsSCOTT J. DYLLA, MARIANNE SANTAGUIDA, WADE C. ANDERSON, BOB Y. LIU, SAMUEL A. WILLIAMS
Life of this patent
Estimating the term…
Abstract
Markers useful for the identification, characterization and, optionally, the enrichment or isolation of tumorigenic cells or cell subpopulations are disclosed.
Claims20
A tumorigenic cell population enriched for expression of at least one TICAM selected from the group consisting of CA9, CCR4, CCR9, CCRL2, CD32, CD56, CD58, CD102, CD117, CD118, CD131, CD133, CD141, CD146, CD147, CD148, CD156, CD167a, CD177, CD196, CD234, CD244, CD245, CD265, CD299, CD323, CD349, BMPR-1B, Cadherin-11, Claudin-3, Claudin-4, CLEC4A, DLL-1, DLL-3, Eph-A2, Frizzled-1, Frizzled-3, Glut-1, Glut-3, Glypican 1, HLA-A/B/C, HLA-A2, IL-15R, IL-17R, IL-17 RD, Jagged-2, Integrin-a8, LAG-3, Leukotriene-B4R, Lox-1, LRP6, MCSP, M6PR, MMP14, Nectin-4, Notch2, NPC, OV6, P-Cadherin, PAR1, PD-L2, Plexin-B1, Plexin-B2, Plexin-D1, PNPLA2, Somatostatin-R2, TIMD4, TSPAN8, TREM2, TREML1, ULBP2, and VEGFR2.
A method of treating or diagnosing a disorder subject in need thereof comprising the steps of;
- a. obtaining a tumor sample from the subject;
- and
- b. contacting the tumor sample with at least one binding agent that preferably associates with a TICAM selected from the group consisting of CA9, CCR4, CCR9, CCRL2, CD32, CD56, CD58, CD102, CD117, CD118, CD131, CD133, CD141, CD146, CD147, CD148, CD156, CD167a, CD177, CD196, CD234, CD244, CD245, CD265, CD299, CD323, CD349, BMPR-1B, Cadherin-11, Claudin-3, Claudin-4, CLEC4A, DLL-1, DLL-3, Eph-A2, Frizzled-1, Frizzled-3, Glut-1, Glut-3, Glypican 1, HLA-A/B/C, HLA-A2, IL-15R, IL-17R, IL-17 RD, Jagged-2, Integrin-a8, LAG-3, Leukotriene-B4R, Lox-1, LRP6, MCSP, M6PR, MMP14, Nectin-4, Notch2, NPC, OV6, P-Cadherin, PAR1, PD-L2, Plexin-B1, Plexin-B2, Plexin-D1, PNPLA2, Somatostatin-R2, TIMD4, TSPAN8, TREM2, TREML1, ULBP2, and VEGFR2.
A method of generating an immune response in a subject in need thereof comprising the step of exposing the subject's immune system to one or more TICAM whereby the subject develops a protective immune response.
A method for detecting the presence of cancer stem cells in a regenerative medicine product comprising stem cells comprising the step of contacting said regenerative medicine product with at least one TICAM binding agent.
Dependencies are inferred from the claim text.